Go or no go? Abbvie, Roche and Kala await key decisions
One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.
Aurinia sees another way forward for voclosporin
Aurinia's lead project shows promise in its back-up use of dry eye, but risks distracting the company from a late-stage lupus trial.
As the US shutdown rolls on, blockbuster launches line up for 2019
A look at the biggest potential drug launches this year reveals a long list of blockbusters from the likes of Alexion and Abbvie. But what impact will the shutdown have?
Another huge quarter for biotech flotations
Another billion dollar quarter for biotech IPOs signals that investor appetite for high-risk offerings is strong.
